In a report published Tuesday, Canaccord Genuity analyst Scott Van Winkle initiated coverage on Enzymotec Ltd. ENZY with a Buy rating and $24.00 price target.
In the report, Canaccord Genuity noted, “We believe Enzymotec is well positioned to drive sustained growth in the highly attractive nutrition market, translating into strong sales, margin and earnings momentum. Its Vaya segment is purely an incremental opportunity not yet factored into the valuation.”
Enzymotec Ltd. closed on Monday at $17.81.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in